Given that there is no cure for gonorrhea, early detection of this disease, effective treatment and informing sexual partners are the key to controlling the spread of the disease. However, Neisseria gonorrheae have developed resistance to all types of antibiotics since the first treatment with them in the 1930s.
As a first-line treatment, current guidelines recommend either monotherapy with ceftriaxone or a combination of azithromycin but resistance or reduction to both has been reported worldwide in recent years.
In the speed of their communication published on Euro sa idoPleininger et al described the case of a highly potent form of the drug (XDR) Neisseria gonorrheae recently discovered that showed high resistance to azithromycin and resistance to ceftriaxone, cefixime, cefotaxime, ciprofloxacin and tetracycline.
The virus was discovered after a male patient in Austria showed signs of the disease in April 2022 as a result of unprotected sex with a sex worker in Cambodia. The authors noted the potential failure of gonorrhea treatment with ceftriaxone and azithromycin as no gonococcal isolation was found after treatment. After the first course of treatment, the drug test was not successful, but the polymerase chain reaction from the urethra culture swab sample was positive for Neisseria gonorrheae.
XDR gonorrhea challenges current treatment options and recommendations
According to Pleininger at al, isolated genetic studies confirm a species discovered in Austria as a second world gonococcal form with ceftriaxone resistance with high levels of azithromycin and a close relationship. WHO Q “. The “WHO Q” type has been linked to three cases of gonorrhea reported in the UK and Australia in 2018 with reports of links to Southeast Asia.
Multidrug- and many drug resistance Neisseria gonorrheae is a global public health concern given its limited treatment options. Proliferation as described by Pleininger et al with continued proliferation may cause most gonorrhea cases to be incurable.
To address this, the authors conclude that “improved monitoring of bacterial resistance (including clinical trials and supplementation). full-genome alignment), in countries and territories, especially in Asia where many types of ceftriaxone resistance have been described, are of greater importance. Ultimately, new vaccines for effective treatment of gonorrhea and / or adequate gonococcal prevention will be essential.
Pleininger et al, Long-acting (XDR) Neisseria gonorrhoeae causes gonorrhea failure with ceftriaxone and azithromycin in Austria, April 2022, Euro sa ido (2022). DOI: 10.2807 / 1560-7917.ES.2022.27.24.2200455
Provided by the European Center for Disease Control (ECDC).
hint: New strain-resistant Neisseria gonorrhoeae species discovered in Austria (2022, June 16) Retrieved 16 June 2022 from https://medicalxpress.com/news/2022-06-strain-extensively-drug-resistant -neisseria-gonorrhoeae. html
This document is copyrighted. Apart from any genuine transaction for the purpose of personal analysis or investigation, no part may be reproduced without our written permission. Content is provided for informational purposes only.
New strain of extensively drug-resistant Neisseria gonorrhoeae detected in Austria Source link New strain of extensively drug-resistant Neisseria gonorrhoeae detected in Austria